Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > BUSINESS
BUSINESS
- Domestic Drug Makers Need to Break from Closed Innovation and Promote Open Innovation: Prof. Teranishi of Kyoto Univ. MIC
December 13, 2012
- [Data] Sales of Takeda’s Mainstay Products in 1st Half of FY2012
December 13, 2012
- [Data] Sales of Daiichi Sankyo’s Mainstay Products in 1st Half of FY2012
December 13, 2012
- [Data] Sales of Otsuka HD’s Mainstay Products in 1st Half of FY2012
December 13, 2012
- [Data] Sales of Astellas’s Mainstay Products in 1st Half of FY2012
December 13, 2012
- [Data] Sales of Eisai’s Mainstay Products in 1st Half of FY2012
December 13, 2012
- [Data] Sales of Dainippon Sumitomo’s Mainstay Products in 1st Half of FY2012
December 13, 2012
- [Data] Sales of Mitsubishi Tanabe’s Mainstay Products in 1st Half of FY2012
December 13, 2012
- [Data] Sales of Taisho HD’s Mainstay Products in 1st Half of FY2012
December 13, 2012
- [Data] Sales of Kyorin HD’s Mainstay Products in 1st Half of FY2012
December 13, 2012
- [Data] Sales of Shionogi’s Mainstay Products in 1st Half of FY2012
December 13, 2012
- [Data] Sales of Ono’s Mainstay Products in 1st Half of FY2012
December 13, 2012
- [Data] Sales of Santen’s Mainstay Products in 1st Half of FY2012
December 13, 2012
- [Data] Sales of Kaken’s Mainstay Products in 1st Half of FY2012
December 13, 2012
- [Data] Sales of Mochida’s Mainstay Products in 1st Half of FY2012
December 13, 2012
- [Data] Sales of Nippon Shinyaku’s Mainstay Products in 1st Half of FY2012
December 13, 2012
- [Data] Sales of Zeria’s Mainstay Products in 1st Half of FY2012
December 13, 2012
- [Data] Sales of Kissei’s Mainstay Products in 1st Half of FY2012
December 13, 2012
- [Data] Sales of Fuso's Mainstay Products in 1st Half of FY2012
December 13, 2012
- [Data] Sales of ASKA's Mainstay Products in 1st Half of FY2012
December 13, 2012
ページ
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…